Sermorelin + Ipamorelin 10mg

1. 1

   Draw exactly 3.0 mL of bacteriostatic water using a sterile syringe.

2. 2

   Introduce the diluent slowly against the inside glass wall of the vial to minimize agitation.

3. 3

   Swirl the vial gently until the lyophilized cake fully dissolves, avoiding vigorous shaking.

4. 4

   Affix a label indicating the reconstitution date, the 3,333 mcg/mL total concentration, and the 1:1 constituent ratio.

5. 5

   Refrigerate the dissolved blend at 2–8 °C, shielded from light exposure.

Overview

The Sermorelin and Ipamorelin composite combines an active growth hormone-releasing hormone fragment with a selective ghrelin receptor agonist within a unified 10 mg lyophilized formulation. By targeting distinct receptors on the anterior pituitary, the combination is frequently investigated for its potential to trigger complementary intracellular cascades, thereby accentuating endogenous growth hormone pulses without disrupting baseline physiological rhythmicity. Sermorelin corresponds to the truncated 29-amino-acid bioactive terminal of endogenous GHRH, primarily responsible for setting pulse amplitude. In contrast, ipamorelin functions via the secretagogue receptor GHS-R1a to induce hormone discharge without significantly provoking secondary adrenocorticotropic or prolactin pathways. Integrating both entities at an equal mass ratio enables researchers to explore multivalent secretagogue dynamics from a single combined experimental preparation. Because this blend provides both agents in an unalterable 1:1 proportion, investigation is restricted to fixed-ratio paradigms. The protocol outlines standard laboratory preparation guidelines, measurement equivalents on U-100 syringes, and volumetric titration frameworks suited for in vitro and comparative physiological models.

1. 1.Thorner et al., J Clin Endocrinol Metab, 1996 — Pediatric multicenter evaluation of GHRH(1-29) on growth velocity
2. 2.FDA determination, Federal Register, 2013 — Discontinuation status and safety review of sermorelin acetate
3. 3.Soule et al., J Clin Endocrinol Metab, 1994 — Comparative clearance kinetics of native GHRH(1-29) versus analogs
4. 4.Achermann et al., Clin Endocrinol, 1999 — Continuous GHRH infusion impact on endogenous GH pulse amplitude
5. 5.Raun et al., Eur J Endocrinol, 1998 — Endocrine selectivity and receptor characterization of ipamorelin
6. 6.Gobburu et al., Pharm Res, 1999 — Intravenous pharmacokinetics and pharmacodynamics of ipamorelin in humans
7. 7.Popovic et al., J Clin Endocrinol Metab, 1995 — Synergistic interaction between GHRH and GH secretagogues
8. 8.Ghigo et al., Ann Med, 1998 — Comprehensive review of GH secretagogue action and GHRH synergy
9. 9.Massoud et al., Clin Endocrinol, 1997 — Secretagogue efficacy under high-dose somatostatin infusion
10. 10.WADA, Prohibited List, 2026 — S2 classification of growth hormone secretagogues and releasing factors
11. 11.The Medical Letter, Med Lett Drugs Ther, 1999 — Clinical profile and documented adverse events of sermorelin

Peptide VialView

Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.